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Abstract

The Zn K-edge extended X-ray absorption fine structure (EXAFS) spectra, of the dapE-encoded N-succinyl-l,ldiaminopimelic acid desuccinylase (DapE) from Haemophilus influenzae have been recorded in the presence of
one or two equivalents of Zn(II) (i.e. [Zn_(DapE)] and [ZnZn(DapE)]). The Fourier transforms of the Zn EXAFS are
dominated by a peak at ca. 2.0 Å, which can be fit for both [Zn_(DapE)] and [ZnZn(DapE)], assuming ca. 5 (N,O)
scatterers at 1.96 and 1.98 Å, respectively. A second-shell feature at ca. 3.34 Å appears in the [ZnZn(DapE)]
EXAFS spectrum but is significantly diminished in [Zn_(DapE)]. These data show that DapE contains a dinuclear
Zn(II) active site. Since no X-ray crystallographic data are available for any DapE enzyme, these data provide the
first glimpse at the active site of DapE enzymes. In addition, the EXAFS data for DapE incubated with two
competitive inhibitors, 2-carboxyethylphosphonic acid and 5-mercaptopentanoic acid, are also presented.

According to recent estimates from the United States Centers for Disease Control and Prevention (the CDC),
more than 10 million people died worldwide from bacterial infections in 1995.1 Tuberculosis, for example, was
the leading cause of death in adults by an infectious disease.2 The importance of developing new drugs to fight
infectious disease, such as tuberculosis, is underscored by the emergence of several pathogenic bacterial strains
that are resistant to all currently available antibiotics.3-6 To overcome bacterial resistance to antibiotics, new
enzyme targets must be located and small-molecule inhibitors developed. The meso-diaminopimelate
(mDAP)/lysine biosynthetic pathway offers several potential anti-bacterial targets that have yet to be explored.79
Since both products of this pathway, mDAP and lysine, are essential components of the peptidoglycan cell wall
in Gram-negative and some Gram-positive bacteria, inhibitors of enzymes within this pathway may provide a
new class of antibiotics.5 The fact that there are no similar pathways in mammals suggests that inhibitors of
enzymes in the mDAP/lysine pathway will provide selective toxicity against bacteria and will potentially have
little or no effect on humans.
One of the enzymes in this pathway,10 the dapE-encoded N-succinyl-l,l-diaminopimelic acid desuccinylase
(DapE), catalyzes the hydrolysis of N-succinyl-l,l-diaminopimelate to l,l-diaminopimelate and succinate.11 It has

been shown that deletion of the gene encoding DapE is lethal to Helicobacter pylori and Mycobacterium
smegmatis.12,13 Even in the presence of lysine-supplemented media, the DapE deletion cell line of H. pylori was
unable to grow. Therefore, DapEs are essential for cell growth and proliferation. Since no structural data of any
kind are available for DapE enzymes, we have recorded the Zn K-edge extended X-ray absorption fine structure
(EXAFS) spectra of the DapE from H. influenzae in the presence of one or two equivalents of Zn(II) (i.e.
[Zn_(DapE)] and [ZnZn(DapE)]) (Figure 1). For [ZnZn(DapE)] the EXAFS data report an average of both metal ion
environments. The Fourier transforms of both [Zn_(DapE)] and [ZnZn(DapE)] are dominated by a peak at ca. 2.0
Å, that can be fit for both [Zn_(DapE)] and [ZnZn(DapE)] assuming 5 (N,O) scatterers, at 1.96 and 1.98 Å,
respectively (Fits 1,3; Table 1). A second shell feature at ca. 3.3 Å appears in the [ZnZn(DapE)] EXAFS spectrum
but is significantly diminished in [Zn_(DapE)]. Fits incorporating a Zn−Zn interaction at 3.34 Å for [ZnZn(DapE)]
have reasonable Debye−Waller factors (Fit 4; Table 1) and resulted in a significant improvement in goodness-offit values (f ‘). Therefore, the second-shell FT feature observed at 3.34 Å is consistent with a dinuclear Zn(II)
active site in DapE. Although fits for [Zn_(DapE)] that include a Zn−Zn interaction improve the f ‘ values slightly,
the Debye−Waller factor value for this interaction is significantly higher than for the same interaction in
[ZnZn(DapE)] (cf. Fits 2,4; Table 1).

Figure 1 Zn K-edge X-ray absorption spectra for [Zn_(DapE)] (dashed) and [ZnZn(DapE)] (solid). (A) Zn edge
spectra; (B) k3-weighted Zn EXAFS; (C) Fourier transforms over k = 2−13 Å-1, with S phase correction.

Figure 2 Zn K-edge X-ray absorption spectra of [ZnZn(DapE)] in the absence (black) and presence of CEPA (blue)
or MSPA (red) and [ZnZn(APP)] in the presence of LPA (green). (A) Zn edge spectra; (B) k3-weighted Zn EXAFS; (C)
Fourier transforms over k = 2−13 Å-1, with S phase correction.
Table 1. Curve-Fitting Results for Zn EXAFSa of DapE Enzymes
sample filename (k range) Δk3χ
[Zn_(DapE)]
ZDZ0A (2−13 Å-1)
Δk3χ = 10.23
[ZnZn(DapE)]
ZDZ0A (2−13 Å-1)
Δk3χ = 10.44
[ZnZn(AAP)]
ZAZZA (2−13 Å-1)
Δk3χ = 9.47
[ZnZn(DapE)]-CEPA
ZDZ0A (2−13 Å-1)
Δk3χ = 9.89
[ZnZn(AAP)]-LPA
ZAZPA (2−13 Å-1)
Δk3χ = 9.91

fit
1
2

shell
Ras (Å) σas2 (Å2) ΔE0 (eV) f ‘ b
Zn−O5 1.96
0.0062 −9.11
0.104
Zn−O5 1.96
0.0062 −9.30
0.100
Zn−Zn 3.30
0.0117
3 Zn−O5 1.98
0.0065 −9.01
0.111
4 Zn−O5 1.98
0.0064 −9.41
0.093
Zn−Zn 3.34
0.0051
5 Zn−O5 1.99
0.0084 −8.71
0.094
6 Zn−O5 1.99
0.0084 −9.12
0.089
Zn−Zn 3.27
0.0099
7 Zn−O5 1.99
0.0069 −8.00
0.096
8 Zn−O5 1.99
0.0085 −8.42
0.088
Zn−Zn 3.34
0.0083
9 Zn−O5 1.99
0.0078 −8.22
0.108
10 Zn−O5 1.99
0.0077 −8.56
0.103
Zn−Zn 3.30
0.0112
11 Zn−O5 1.99
0.0077 −8.49
0.103
Zn−Zn 3.80
0.0072
[ZnZn(DapE)]-MSPA
12 Zn−O5 1.99
0.0079 −3.03
0.109
ZDZTA (2−13 Å-1)
13 Zn−O5 1.99
0.0050 −6.24
0.097
3
Δk χ = 9.98
Zn−S
2.30
0.0089
Zn−Zn 3.64
0.0083
a
Shell is the chemical unit defined for the multiple scattering calculation, the number of scatterers per metal
denoted by the subscript. Ras is the metal-scatterer distance. σas2 is a mean square deviation in Ras. ΔE0 is the
shift in E0 for the theoretical scattering functions.b f ‘ is a normalized error (χ-squared): f‘ =
{∑i[k3(−)]2/N}1/2/[(k3χobs)max − (k3χobs)min].

Sequence alignments of several DapE genes with those of the crystallographically characterized aminopeptidase
from Aeromonas proteolytica (AAP) and the carboxypeptidase G2 from Pseudomonas sp. strain RS-16 (CPG2),
indicate that all of the amino acids that function as metal ligands in AAP and CPG2 are strictly conserved in
DapEs.11,14-16 The X-ray crystal structures of both CPG2 and AAP reveal a (μ-aquo)(μ-carboxylato)dizinc(II) active
site with one terminal carboxylate and histidine residue bound to each metal ion.15,16 Both Zn(II) ions in AAP and
CPG2 reside in a distorted tetrahedral coordination geometry, with a Zn−Zn distance of 3.5 and 3.3 Å for AAP and
CPG2, respectively.15,16 EXAFS data obtained for [ZnZn(AAP)] also contain a feature at 3.27 Å that can be modeled
as a Zn−Zn vector (Fit 6; Table 1). Combination of these data indicates that DapE enzymes contain dinuclear
Zn(II) active sites. In addition, on the basis of the first shell fits of [ZnZn(AAP)] and [ZnZn(DapE)], we propose that
one carboxylate and one histidine residue resides at each Zn(II) site in DapE and that the two Zn(II) ions are
bridged by one carboxylate residue and a water molecule.
The first step in inhibitor design for DapE enzymes requires an understanding of how inhibitors bind to the
active site. Therefore, we recorded the Zn K-edge EXAFS spectra of [ZnZn(DapE)] in the presence of the
competitive inhibitors 2-carboxyethylphosphonic acid (CEPA) and 5-mercaptopentanoic acid (MSPA) (Figure 2).
The EXAFS data for [ZnZn(DapE)]−CEPA indicate that the average coordination number of each Zn(II) ion remains
five and the Zn−Zn distance remains 3.34 (Fits 7,8; Table 1). An increase in the M−M distance of [ZnZn(AAP)],
from 3.5 to 3.9 Å, is observed upon the addition of the transition-state analogue inhibitor l-leucine-phosphonic
acid (LPA) which contains a similar ligating group to CEPA.17 The X-ray crystal structure and EXAFS data for
[ZnZn(AAP)]-LPA, reveal that the bridging water molecule is displaced by LPA resulting in an η-1,2-μphosphonate bridge and an increase in the Zn−Zn distance of 0.4 Å (Fit 11; Table 1). The fact that the Zn−Zn
distance does not change upon CEPA binding to [ZnZn(DapE)] suggests an η-1-μ-phosphonate bridge exists,
similar to the binding mode of LPA to the leucine aminopeptidase from bovine lens.17,18 On the other hand,
MSPA binding to [ZnZn(DapE)] has a marked effect on the Zn K-edge, suggesting that the average electronic
environment of the dinuclear Zn(II) site has changed significantly (Figure 2). The observed shift to lower energy
in the absorption edge position is indicative of a net increase in electron density at the dinuclear Zn(II) site,
consistent with a sulfur ligand. In addition, the EXAFS data for [ZnZn(DapE)]−MSPA reveal a new feature at 2.3 Å
that is highly characteristic of a direct zinc−sulfur interaction (Fits 12,13; Table 1). Moreover, the M−M distance
is lengthened from 3.34 to 3.64 Å. These data indicate that the thiol group of MSPA binds to one or more of the
Zn(II) ions in the active site of DapE.
In conclusion, DapEs are potential molecular targets for a new and novel class of antibiotics. The EXAFS data
presented herein provide the first structural information for any DapE enzyme and also establish the binding
modes of phosphonate- and thiolate-containing inhibitors. In addition, the structural data obtained for CEPA
bound to [ZnZn(DapE)] provide the first glimpse at the transition state of the hydrolysis reaction catalyzed by
DapE. Since most pharmaceuticals target the transition state of enzymatic reactions, the structural aspects of
[ZnZn(DapE)]−CEPA are particularly important for the rational design of new potent inhibitors of DapE enzymes.
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